<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>cisplatin &#8211; Head and Neck Network</title>
	<atom:link href="https://headandnecknetwork.com/tag/cisplatin/feed/" rel="self" type="application/rss+xml" />
	<link>https://headandnecknetwork.com</link>
	<description></description>
	<lastBuildDate>Mon, 12 Jan 2026 09:43:55 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://headandnecknetwork.com/wp-content/uploads/2025/01/cropped-favicon-32x32.jpg</url>
	<title>cisplatin &#8211; Head and Neck Network</title>
	<link>https://headandnecknetwork.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Enhancing audiometric surveillance in head and neck cancer patients undergoing cisplatin-based chemoradiation</title>
		<link>https://headandnecknetwork.com/enhancing-audiometric-surveillance-in-head-and-neck-cancer-patients-undergoing-cisplatin-based-chemoradiation/</link>
					<comments>https://headandnecknetwork.com/enhancing-audiometric-surveillance-in-head-and-neck-cancer-patients-undergoing-cisplatin-based-chemoradiation/#respond</comments>
		
		<dc:creator><![CDATA[Head &#38; Neck]]></dc:creator>
		<pubDate>Mon, 12 Jan 2026 09:43:55 +0000</pubDate>
				<category><![CDATA[health]]></category>
		<category><![CDATA[medical research]]></category>
		<category><![CDATA[audiometricmonitoring]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[headandneckcancer]]></category>
		<category><![CDATA[headandnecknetwork]]></category>
		<category><![CDATA[ototoxicity]]></category>
		<guid isPermaLink="false">https://headandnecknetwork.com/?p=1898</guid>

					<description><![CDATA[Cisplatin-based chemoradiation remains a cornerstone in the treatment of head and neck cancers (HNCs), but its use is frequently associated with ototoxicity, characterized by high-frequency sensorineural hearing loss, tinnitus, and occasionally vestibular dysfunction. Audiometric monitoring protocols are inconsistently implemented across oncology centres and are often limited to cases in which symptoms have already developed. Early [&#8230;]]]></description>
										<content:encoded><![CDATA[<p class="p1">Cisplatin-based chemoradiation remains a cornerstone in the treatment of head and neck cancers (HNCs), but its use is frequently associated with ototoxicity, characterized by high-frequency sensorineural hearing loss, tinnitus, and occasionally vestibular dysfunction.</p>
<p class="p1"><span class="s2">Audiometric monitoring protocols are inconsistently implemented across oncology centres and are often limited to cases in which symptoms have already developed.</span></p>
<p class="p1"><span class="s2">Early identification of audiometric shifts enables clinicians to consider dose adjustments, treatment modifications, or otoprotective strategies without compromising oncologic efficacy. <img fetchpriority="high" decoding="async" class="size-medium wp-image-1899 alignleft" src="https://headandnecknetwork.com/wp-content/uploads/2026/01/Immagine-Instagram-225x300.png" alt="" width="225" height="300" srcset="https://headandnecknetwork.com/wp-content/uploads/2026/01/Immagine-Instagram-225x300.png 225w, https://headandnecknetwork.com/wp-content/uploads/2026/01/Immagine-Instagram-768x1024.png 768w, https://headandnecknetwork.com/wp-content/uploads/2026/01/Immagine-Instagram.png 1080w" sizes="(max-width: 225px) 100vw, 225px" /></span></p>
<p class="p1"><span class="s2">Recent data show that fewer than 5% of adult patients receiving cisplatin adhere to these protocols fully. Recent years have seen advances in both ototoxicity prevention and monitoring. </span></p>
<p class="p1"><span class="s2">This study published in the journal </span><span class="s2">CCO &#8211; CHINESE CLINICAL ONCOLOGY calls for solving this issue for the benefit of patients, based on data indicating that the inclusion of audiologists or audiometrists in oncology committees and care teams is not a luxury but a necessity.</span></p>
<p class="p1"><span class="s2">Structured, timely audiometric surveillance ensures that hearing loss is detected early, addressed effectively, and managed comprehensively, thereby preventing irreversible damage, enabling clinicians to balance oncologic efficacy with long-term quality of life.</span></p>
<p class="p1"><span class="s2">Authors: @dottraffaeleaddeo on Instagram </span></p>
<p class="p1"><span class="s2">Aurora Mirabile Medical Oncologist</span></p>
<p class="p1"><span class="s2">Full article 👇</span></p>
<p class="p1"><span class="s2"><a href="https://cco.amegroups.org/article/view/147223/html" rel="nofollow noopener" target="_blank">https://cco.amegroups.org/article/view/147223/html</a></span></p>
]]></content:encoded>
					
					<wfw:commentRss>https://headandnecknetwork.com/enhancing-audiometric-surveillance-in-head-and-neck-cancer-patients-undergoing-cisplatin-based-chemoradiation/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
